阿司匹林使用与降低草发热或过敏性鼻炎风险之间的潜在因果关系:孟德尔的随机化研究
Li Li1, Yuanding Zhang1, Xiangliang Liu2
1Department of Otolaryngology-Head and Neck Surgery, Lequn Branch, The First Hospital of Jilin University, Changchun, China.
Frontiers in immunology
|September 11, 2023
概括
阿司匹林的使用可能会因果性地降低山热和过敏性鼻炎的风险. 这项门德尔随机化研究提供了保护性关联的证据,表明对过敏患者的潜在益处.
科学领域:
- 流行病学 流行病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 观察性研究显示,阿司匹林对草发热风险的影响有相互矛盾的证据.
- 缺乏高质量的随机对照试验来证实这一关联.
研究的目的:
- 调查阿司匹林使用与患花粉热或过敏性鼻炎的风险之间的潜在因果关系.
- 利用门德尔的随机化来克服观察性研究的局限性.
主要方法:
- 进行了两样本的孟德尔随机化分析.
- 使用全基因组关联研究 (GWAS) 的阿司匹林使用 (n=337,159) 和过敏性鼻炎 (n=83,529) 的数据.
- 应用了反变量加权,加权中位数和MR-Egger方法.
主要成果:
- 反变量加权和加权中位数方法表明,阿司匹林使用与过敏性鼻炎风险降低之间存在因果关系.
- 通过MR-Egger回归,没有发现显著的因果关系.
- 没有检测到任何显著的异质性或质性.
结论:
- 研究结果表明,阿司匹林使用与降低山热或过敏性鼻炎的风险之间存在潜在的因果关系.
- 进一步的研究可能会探索阿司匹林在治疗过敏症的治疗潜力.
相关概念视频
Criteria for Causality: Bradford Hill Criteria - II
359
The Bradford Hill criteria serve as guidelines for establishing causative links in epidemiological research. Beyond Strength, Consistency, Specificity, and Temporality, key criteria also include Biological Gradient, Plausibility, Coherence, Experiment, and Analogy. These principles assist scientists in assessing the likelihood of causation in complex biological contexts. Below is a summary of these concepts:
359
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
332
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
332
Allergic Reactions
27.7K
Overview
27.7K
Upper Respiratory Drugs: First and Second-Generation Antihistamines
320
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
320


